000			03595nam a22004095i 4500
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
999			_c99906 _d99906 _x1
001			99906
003			DE-He213
005			20230110040156.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			171017s2018 si | s |||| 0|eng d
020			_a9789811044663
024	7		_a10.1007/978-981-10-4466-3 _2doi
040			_aES-MaUEC _bspa _dES-MaUEC
050		4	_aRD539 _b.D784 2018 EB
245	1	0	_aDrug-Induced Lung Injury _cedited by Masayuki Hanaoka, Hiroyuki Nakamura, Kazutetsu Aoshiba.
264		1	_aSingapore _bSpringer International Publishing _c2018
300			_a1 recurso en línea (VIII, 215 páginas 53 ilustraciones, 15 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aRespiratory Disease Series: Diagnostic Tools and Disease Managements _x2509-5552
490	0		_aMedicine (Springer-11650)
505	0		_aPart I　Definition, Pathogenesis, and Epidemiology -- 1. Definition, Pathogenesis and Epidemiology: What is DLI? -- 2. Epidemiology and Risk Factors of Drug-Induced Lung Disease: What are the prevalence and risk factors of DLI? -- 3. Clinical Characteristics of DLI: What are the clinical features of DLI? -- Part II　Diagnosis -- 4. Diagnostic Approach for DLI: How is DLI diagnosed? -- 5. Blood tests for the diagnosis and/or management of DLI: What are the clinical significances of KL-6, SP-A, SP-D and DLST in DLI? -- 6. Imaging features of drug-induced interstitial lung disease: How HRCT of DLI is interpreted? -- 7. Pathology of DLI: What is the pathological significance of DLI? -- 8. Differential Diagnosis of DLI: What are the differential diagnoses of DLI? -- Part II　Treatment -- 9. Therapeutic Strategies for DLI: How should DLI be treated? -- Part IV　Drugs Causing DLI -- 10. DLI induced by non-molecular target antineoplastic drugs: What are the characteristics of DLI in non-molecular target antineoplastic drugs? -- 11. DLI induced by Molecular Target Antineoplastic Drug: What are the characteristics of DLI in molecular target antineo-plastic drugs? -- 12. DLI caused by disease-modifying antirheumatic drugs: What are the characteristics of DLI by disease-modifying antirheumatic drugs? -- 13. DLI Induced by Herbal Medicine: What are the characteristics of DLI due to herbal medicines? -- 14. DLI induced by Antiarrhythmic Drug and Antimicrobial Drug: What are the characteristics of DLI in antiarrhythmic drugs and antimicrobial drugs?.
988			_aSpringer_Medicine_2018
650		7	_aPulmones _xEnfermedades _2embne _9168957
700	1		_aHanaoka, Masayuki _eeditor literario _0http://id.loc.gov/authorities/names/n2018183958 _0http://viaf.org/viaf/117152742960827731715
700	1		_aNakamura, Hiroyuki _eeditor literario _0http://id.loc.gov/authorities/names/n2016181312 _0http://viaf.org/viaf/254081071 _9100388
700	1		_aAoshiba, Kazutetsu _eeditor literario _0http://id.loc.gov/authorities/names/n2016181310 _0http://viaf.org/viaf/763144928093154341103 _9100389
776	0	8	_iEdición impresa: _z9789811044656
776	0	8	_iEdición impresa: _z9789811044670
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-4466-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2019 _dz _ef _feng _ggw _h0